A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors (NF112)
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Durvalumab (Primary) ; Selumetinib (Primary) ; SRA 515 (Primary)
- Indications Ewing's sarcoma; Malignant fibrous histiocytoma; Neurofibrosarcoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 08 Jun 2025 Planned End Date changed from 15 Jun 2031 to 15 Dec 2031.
- 08 Jun 2025 Planned primary completion date changed from 15 Jun 2030 to 15 Dec 2030.
- 08 Jun 2025 Planned initiation date changed from 15 Jun 2025 to 15 Dec 2025.